Zhang Yuntao, Tan Wenjie, Lou Zhiyong, Zhao Yuxiu, Zhang Jin, Liang Hongyang, Li Na, Zhu Xiujuan, Ding Ling, Huang Baoying, Zhou Weimin, Guo Yancen, Yang Zhaona, Qiao Yuling, He Zhenyu, Ma Bo, He Yao, Zhu Di, Wang Zhanhui, Chang Zhen, Zhao Xue, Wang Wei, Xu Ying, Zhu Huiqin, Zheng Xiaotong, Wang Chenlong, Xu Guangxue, Wu Guizhen, Wang Hui, Yang Xiaoming
Beijing Institute of Biological Products Company Limited, Beijing 100176, China.
China National Biotec Group Company Limited, Beijing 100024, China.
Vaccines (Basel). 2022 Jul 19;10(7):1149. doi: 10.3390/vaccines10071149.
In response to the fast-waning immune response and the great threat of the Omicron variant of concern (VOC) to the public, we report the pilot-scale production of an inactivated Omicron vaccine candidate that induces high levels of neutralizing antibody titers to protect against the Omicron virus. Here, we demonstrate that the inactivated Omicron vaccine is safe and effective in recalling immune responses to the HB02, Omicron, and Delta viruses after one or two doses of BBIBP-CorV. In addition, the efficient productivity and good genetic stability of the manufactured inactivated vaccine is proved. These results support the further evaluation of the Omicron vaccine in a clinical trial.
针对快速减弱的免疫反应以及受关注的奥密克戎变异株（VOC）对公众的巨大威胁，我们报告了一种灭活奥密克戎候选疫苗的中试规模生产情况，该疫苗可诱导高水平的中和抗体滴度以预防奥密克戎病毒。在此，我们证明了灭活奥密克戎疫苗在接种一剂或两剂BBIBP-CorV后，在唤起对HB02、奥密克戎和德尔塔病毒的免疫反应方面是安全有效的。此外，还证明了所生产的灭活疫苗具有高效的生产力和良好的遗传稳定性。这些结果支持在临床试验中对奥密克戎疫苗进行进一步评估。
Zotero 插件
